logo 600X600.png
Global Heparin Calcium Market to Surpass US$ 1,700.8 Million by 2030, Says Coherent Market Insights (CMI)
February 15, 2023 09:15 ET | CMI
Burlingame, Feb. 15, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global heparin calcium market is estimated to be valued at US$ 1,370.9 in 2022 and is expected to exhibit a...
Holter ECG Market Size Report ($1.21 Billion by 2028) Driven by Rising Prevalence of CVDs – Exclusive Report by The Insight Partners
February 06, 2023 08:36 ET | The Insight Partners
New York, Feb. 06, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Holter ECG Market Size, Share, Growth, Trends and Global Forecast to 2028 - COVID-19 Impact and Global Analysis by...
Global Atrial Fibrillation Market Report 2022 to 2028: Increasing Prevalence of Obesity and Cardiac Disorders Drives Growth
January 19, 2023 04:03 ET | Research and Markets
Dublin, Jan. 19, 2023 (GLOBE NEWSWIRE) -- The "Global Atrial Fibrillation Market Size, Share & Industry Trends Analysis Report by End-user, Type, Technology, Regional Outlook and Forecast,...
Anthos Logo Transparent.png
First Patient Enrolled in Phase 3 Trial Evaluating Abelacimab in High-Risk Patients with Atrial Fibrillation Deemed Unsuitable for Current Anticoagulants
January 03, 2023 08:00 ET | Anthos Therapeutics
FDA Fast-Track designation was granted to investigate abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation LILAC-TIMI 76 trial is the third Phase 3...
Global Atrial Fibrillation Treatment Market
Outlook on the Atrial Fibrillation Treatment Global Market to 2027 - Rising Prevalence of Cardiovascular Diseases Drives Growth
December 22, 2022 06:38 ET | Research and Markets
Dublin, Dec. 22, 2022 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ...
Left Atrial Appendage Closure Devices Market worth USD 4.5 Billion by 2032, says Global Market Insights Inc.
November 21, 2022 05:40 ET | Global Market Insights Inc.
Selbyville, Delaware, Nov. 21, 2022 (GLOBE NEWSWIRE) -- The left atrial appendage closure devices market value is set to surpass USD 4.5 billion by 2032, according to a recent report by Global...
InCarda Logo.png
Final Results from Phase 2 INSTANT Trial of InRhythm™ for the Treatment of Newly Diagnosed and Recurrent Paroxysmal Atrial Fibrillation Presented at 2022 American Heart Association Scientific Sessions
November 07, 2022 07:00 ET | InCarda Therapeutics, Inc.
Data Demonstrate Orally Inhaled Flecainide May Provide a Safe, Effective, and Convenient First-Line Treatment Option for Cardioversion of Recent-Onset Newly Diagnosed and Paroxysmal Atrial...
InCarda Logo.png
InCarda Therapeutics Announces Execution of Planned CEO Transition to Drive Next Phase of Corporate Growth
October 04, 2022 07:00 ET | InCarda Therapeutics, Inc.
Robert Lisicki Appointed as New Chief Executive Officer and Board Member; Possesses Broad Commercial and Public Company Experience Grace E, Colón, Ph.D., Stepping Aside Following Nearly Ten Years as...
S4 Medical
S4 Medical Meets Primary Endpoint in Esophagus Deviation During Radiofrequency Ablation of Atrial Fibrillation (EASY AF Study)
September 12, 2022 07:30 ET | S4 Medical Corp
CLEVELAND, Sept. 12, 2022 (GLOBE NEWSWIRE) -- S4 Medical Corp, an Ohio-based company with technology originating from The Ohio State University, announced that it is stopping the Esophagus Deviation...
Logo Volta Medical.png
Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication
August 31, 2022 08:00 ET | Volta Medical
Volta VX1 decision support software reproduces expert-physician electrogram (EGM) analysis that can assist physicians in the real-time identification of specific abnormal electrograms in a persistent...